ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
Tryptamine Therapeutics Ltd (PK)

Tryptamine Therapeutics Ltd (PK) (TYPTF)

0.0201
0.00
(0.00%)
마감 06 3월 6:00AM

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

주요 통계 및 세부정보

가격
0.0201
매수가
0.0201
매도가
0.0201
거래량
-
0.00 일간 변동폭 0.00
0.0007 52주 범위 0.0385
전일 종가
0.0201
개장가
-
최근 거래 시간
마지막 거래 시간
평균 볼륨(3m)
136,419
재정 규모
-
VWAP
-

TYPTF 최신 뉴스

No news to show yet.
기간변동변동 %시가고가저가평균 일일 거래량VWAP
10.008979.46428571430.01120.02010.0112402730.01861732CS
40.000753.875968992250.019350.0250.0112398810.01464978CS
120.0080166.2531017370.012090.0290.011364190.01744174CS
260.01011010.010.03850.00081038180.01818901CS
520.01412350.0060.03850.0007906520.01753744CS
1560.01412350.0060.03850.0007906520.01753744CS
2600.01412350.0060.03850.0007906520.01753744CS

TYPTF - Frequently Asked Questions (FAQ)

What is the current Tryptamine Therapeutics (PK) share price?
The current share price of Tryptamine Therapeutics (PK) is US$ 0.0201
What is the 1 year trading range for Tryptamine Therapeutics (PK) share price?
Tryptamine Therapeutics (PK) has traded in the range of US$ 0.0007 to US$ 0.0385 during the past year

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
AABVFAberdeen International Inc (PK)
US$ 0.028
(0.00%)
0
AABKFAareal Bank AG (CE)
US$ 0.00
(0.00%)
0
AABBAsia Broadband Inc (PK)
US$ 0.0225
(0.00%)
0
AAALYAareal Bank AG (PK)
US$ 34.65
(0.00%)
0
AAAIFAlternative Investment Trust (PK)
US$ 0.55
(0.00%)
0
AABVFAberdeen International Inc (PK)
US$ 0.028
(0.00%)
0
AABKFAareal Bank AG (CE)
US$ 0.00
(0.00%)
0
AABBAsia Broadband Inc (PK)
US$ 0.0225
(0.00%)
0
AAALYAareal Bank AG (PK)
US$ 34.65
(0.00%)
0
AAAIFAlternative Investment Trust (PK)
US$ 0.55
(0.00%)
0
AABVFAberdeen International Inc (PK)
US$ 0.028
(0.00%)
0
AABKFAareal Bank AG (CE)
US$ 0.00
(0.00%)
0
AABBAsia Broadband Inc (PK)
US$ 0.0225
(0.00%)
0
AAALYAareal Bank AG (PK)
US$ 34.65
(0.00%)
0
AAAIFAlternative Investment Trust (PK)
US$ 0.55
(0.00%)
0
Checkmate 36 Checkmate 36 5 분 전
Happy,
100% agree.

This is NWBO’s chance.
There has been a number of frustrated (some more than others) longs who have been left scratching their heads wondering….why????

Why not PR this or that?
Why not submit to NICE, FDA, EU?
Why not do
NWBO
ANTI-BAGHOLDER ANTI-BAGHOLDER 5 분 전

Purchase agreement for $165 million completed 
https://www.otcmarkets.com/otcapi/company
BBLC
Huggy Bear Huggy Bear 6 분 전
More converted shares raining down alert.

Gee, who keeps saying all this dilution is ending - while clearly it is not?
HMBL
uranium-pinto-beans uranium-pinto-beans 6 분 전
Seaport Research analyst Kenneth Zener upgraded five homebuilder stocks to Buy - raising KB Home (KBH) with a $79 price target, Lennar (LEN) with a $154 price target, TRI Pointe (TPH) with a $41 price target, M/I Homes (MHO) with a $151 price target and D.R. Horton (DHI) with a $164 price target - w
DHI KBH
uranium-pinto-beans uranium-pinto-beans 6 분 전
Todays largest decreases in stock option open interest $NVDA $SOFI $NOK $WFC $TSLA $MSTR $AMZN $BAC $LCID
AMZN BAC LCID
dennisdave dennisdave 6 분 전
Past doesn't matter, it doesnt?? ooh wow I will tell my wife this next time I forget to bring the kids to a soccer game
NWBO
HenryB3 HenryB3 6 분 전
Keep drinking the Kool aide. See you at 12 cents. Then what will be the story and year then?
ELTP
Carico13 Carico13 7 분 전
IMO SYTA is going to take off today. Get in while it's cheap
SYTA
ilovetech ilovetech 7 분 전
UCLA researchers unite to develop immunotherapy they hope will transform ovarian cancer treatment March 5, 2025
Key takeaways : (AI Analysis of potential synergy with DCVax technology below)

https://x.com/peter_brit/status/1897575005057130653?t=e1EFma2z-J3ISOx18TOzyw&s=19
NWBO
HappyLibrarian HappyLibrarian 8 분 전
As soon as MHRA approval hits which could be before month’s end (more likely) or could be as long as 3 months more (far less likely but this is NWBO so big delays due to reasons we are kept in dark about can never be off the table).
NWBO
FlyFishingStocks FlyFishingStocks 8 분 전
This is the end game I have been posting since Denner took the reigns. Sarissa has profited by trading mirror image moves in AMRN since Denner took over. They engineered bogus upgrades/ rallies so that they could stomp on retail euphoria and take the price down step by step toward this day.
AMRN
resx18 resx18 8 분 전
Let's keep this train rolling! $CBDW
CBDW
gdog gdog 9 분 전
Rr4627
26m

$NLST Good thing we did not hold our breath, Charls Schwab now shows earnings 3/12/25, we will see.( good things take time?)

1


1
NLST
buysellrepeat buysellrepeat 9 분 전
I really don’t think they are diluting us
ATWT
KISSINGER KISSINGER 9 분 전
Maybe the last 5 times I have explained to you and everyone here did not resonate strongly enough. CG puts his money directly into the company. Not into the hands of some short term flipper that needs optics as he has said to me in the past. If he follwed that philosophy there would be no company.
AHRO
Dr Speculator Ninja Dr Speculator Ninja 9 분 전
Choo-Choo! "Get your tickets for the Bitter Train!" Choo-Choo!

Awww HenryB3, you should have bought at .16..... If you'd only bought $ELTP when you first posted here on August 21, 2024 you would have more than doubled your money and been sitting pretty for the next leg up! But now it
ELTP
TheDane TheDane 10 분 전
Exactly…. “Others may have short term tariff worries

but the big tech companies doing so much

spending already have the correct change...”
SMCI
Stinger2014 Stinger2014 10 분 전
And the dump back to -.30…
BTOG
Bearslayer Bearslayer 11 분 전
If numbers are coming next week shouldn't they have put out a pr about the conference call they touted in the December pr?
NXPL
Paulie Pennies Paulie Pennies 12 분 전
The problem is they have fiduciary responsibilities they solved a good chunk of that over the last six months paying debt... from a non emotional standpoint and strictly speaking from a business perspective I don't see how they have any other choice and responsibility to shareholders to engage in a
ASII
stocktowatch stocktowatch 12 분 전
$CVM News! CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial
Confirmatory Phase 3 Trial Designed to Support Commercialization of Multikine for Head and Neck Cancer Treatment

Full enrollment expected by Q2 2026 with plans to seek early approval at that time based o
CVM
TrendTrade2016 TrendTrade2016 12 분 전
SING HO HUM XI WONG TONG
drugrunner drugrunner 12 분 전
Wow look at the sad librarian /LC I'm not invested 082...  doing their best to create more false narratives POST UK APPROVAL


THE MILESTONE they claimed would never happen is now virtually accepted by the BASHERS now they are creating new narratives they have to have a partners
NWBO

최근 히스토리

Delayed Upgrade Clock